Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Maj 2019

Planlagt Fastgjort Låst Flyttet Genmab
2.0k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • R Offline
    R Offline
    Relax
    wrote on sidst redigeret af
    #340

    Jeg har ikke kendskab til noget firma der har opbygger en salgsorganisation til half the world, og ikke har noget produkt at sælge???

    1 Reply Last reply
    0
    • R Offline
      R Offline
      Relax
      wrote on sidst redigeret af
      #341

      Håber I kan gøre mig klogere...

      1 Reply Last reply
      0
      • Helge_LarsenPI-redaktørH Offline
        Helge_LarsenPI-redaktørH Offline
        Helge_LarsenPI-redaktør
        wrote on sidst redigeret af
        #342

        Relax...Glimrende spørgsmål til Q&A.

        1 Reply Last reply
        0
        • Helge_LarsenPI-redaktørH Offline
          Helge_LarsenPI-redaktørH Offline
          Helge_LarsenPI-redaktør
          wrote on sidst redigeret af
          #343

          Skyd bare løs. 🙂

          1 Reply Last reply
          0
          • Helge_LarsenPI-redaktørH Offline
            Helge_LarsenPI-redaktørH Offline
            Helge_LarsenPI-redaktør
            wrote on sidst redigeret af
            #344

            Just a moment...

            favicon

            (www.proinvestor.com)

            1 Reply Last reply
            0
            • R Offline
              R Offline
              Relax
              wrote on sidst redigeret af
              #345

              Tak Helge:) sætter det ind
              i Q&A

              1 Reply Last reply
              0
              • Helge_LarsenPI-redaktørH Offline
                Helge_LarsenPI-redaktørH Offline
                Helge_LarsenPI-redaktør
                wrote on sidst redigeret af
                #346

                Super. 🙂

                1 Reply Last reply
                0
                • Helge_LarsenPI-redaktørH Offline
                  Helge_LarsenPI-redaktørH Offline
                  Helge_LarsenPI-redaktør
                  wrote on sidst redigeret af
                  #347

                  Husk det skal være på engelsk.

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #348

                    Halo still expecting SC submission this year:

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #349

                      Halozyme Dr. Helen Torley, president and chief executive officer. "Looking ahead in 2019, we expect this momentum to continue. On ENHANZE® we anticipate regulatory submissions by ENHANZE® partner Janssen for the subcutaneous formulation of DARZALEX®

                      1 Reply Last reply
                      0
                      • P Offline
                        P Offline
                        polle1
                        wrote on sidst redigeret af
                        #350

                        Godmorgen og god dag 🙂

                        1 Reply Last reply
                        0
                        • S Offline
                          S Offline
                          Sukkeralf
                          wrote on sidst redigeret af
                          #351

                          E L with the new DKd arm in the phase II kombination study with sc dara it for sure now must be only filing for mono sc dosing this year - and then probably first combination filing next year and if we are unlucky approval in early 2021 for sc dosing in combination

                          1 Reply Last reply
                          0
                          • S Offline
                            S Offline
                            Sukkeralf
                            wrote on sidst redigeret af
                            #352

                            Link Preview Image
                            Medicin til 13 mio kr per behandling rammer markedet i USA

                            En genterapi til muskelsvind hos spædbørn tegner til at tage rekorden for den hidtil dyreste behandling på det amerikanske marked med i pris i omegnen af to mio. dollar.

                            favicon

                            (medwatch.dk)

                            1 Reply Last reply
                            0
                            • S Offline
                              S Offline
                              Sukkeralf
                              wrote on sidst redigeret af
                              #353

                              Måske også et spørgsmål til Jan omkring prispolitikken i USA

                              1 Reply Last reply
                              0
                              • S Offline
                                S Offline
                                Sukkeralf
                                wrote on sidst redigeret af
                                #354

                                Lidt om BCMAs manglende duration:

                                1 Reply Last reply
                                0
                                • S Offline
                                  S Offline
                                  Sukkeralf
                                  wrote on sidst redigeret af
                                  #355

                                  Just a moment...

                                  favicon

                                  (www.firstwordpharma.com)

                                  1 Reply Last reply
                                  0
                                  • S Offline
                                    S Offline
                                    Sukkeralf
                                    wrote on sidst redigeret af
                                    #356

                                    A new study appearing in Leukemia Research from researchers at the Institute for Myeloma & Bone Cancer Research seeking to better understand the phenomenon evaluated 379 samples from relapsed/refractory MM patients and found elevated levels soluble BCMA that were associated with reduced binding by an inhibitory antibody. The group thus suggested that free-floating protein act as a “decoys” that may contribute to diminished efficacy of anti-BCMA therapies.

                                    1 Reply Last reply
                                    0
                                    • S Offline
                                      S Offline
                                      Sukkeralf
                                      wrote on sidst redigeret af
                                      #357

                                      One possible solution to the issue of circulating BCMA that has been proposed is to combine a direct antagonist, be it a CAR-T construct or antibody-based therapy, with an inhibitor of gamma secretase, an enzyme that cleaves transmembrane proteins and is believes to lead to increased levels of soluble BCMA.

                                      1 Reply Last reply
                                      0
                                      • S Offline
                                        S Offline
                                        Sukkeralf
                                        wrote on sidst redigeret af
                                        #358

                                        Novartis is one of the companies that has moved aggressively in this area, partnering to test Ayala Pharmaceuticals’ AL102 in combination with the Swiss pharma’s CAR-T therapy. Juno Therapeutics (acquired by Celgene last year), also licensed a gamma secretase inhibitor from Eli Lilly in late 2017, though Amin noted that nothing has been heard about the programme in the years since.

                                        1 Reply Last reply
                                        0
                                        • S Offline
                                          S Offline
                                          Sukkeralf
                                          wrote on sidst redigeret af
                                          #359

                                          Og nu vi talte om dara i
                                          Kina så seneste update fra MorphoSys: - MOR202: Pivotal phase 2 study in third line and phase 3 study in second line multiple myeloma started by partner I-Mab in Taiwan

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger